The Division of Hematology and Oncology focuses on the diagnosis and treatment of children with cancer or blood diseases. The division also supports a variety of clinical and research programs, a consultation service and a fellowship training program.
Comprehensive specialty programs are available for children with unique needs, including Brain Tumor Program, Experimental Therapeutics, Hemostasis-Thrombosis Clinic, Histiocytosis Program, Sickle Cell Disease Program, Sarcoma Program, REACH for Survivorship Program and Stem Cell Transplant Program.
All our faculty members are board-certified or board-eligible in both Pediatrics and Hematology-Oncology. Several of these outstanding physicians have national leadership roles related to the treatment of childhood cancers. Debra Friedman, M.D., associate professor of Pediatrics and E. Bronson Ingram Chair in Pediatric Oncology leads the division.
The division participates and provides leadership in the development and conduct of COG clinical trials, working with researchers throughout the country to identify cancer causes and novel therapies and treatments. We are associated with The Vanderbilt-Ingram Cancer Center, one of the top-ranked National Cancer Institute-designated comprehensive cancer centers in the United States.
Current research interests include innovative stem cell transplant preparative regimens, coagulation assays, novel therapeutic interventions and chemotherapy disposition. In addition, the division is developing a robust program on cancer survivorship and outcomes research, with multiple collaborators both inside and outside the department and institution.
Be a national leader in offering family-centered, exceptional patient care and translational research, where innovative therapies are rapidly brought to the bedside.
Last Edited: April 18, 2018